Brett Lauring,Samuel S. Engel,Steven G. Terra,James M. Rusnak
申请号：
US16597894
公开号：
US20200038368A1
申请日:
2019.10.10
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to the use of certain SGLT-2 inhibitors, such as ertugliflozin or a pharmaceutically acceptable salt or a co-crystal thereof, for treating, reducing the risk of and/or preventing heart failure, myocardial infarction, cardiovascular disease or cardiovascular death in animals without type 2 or type 1 diabetes mellitus, or in animals with pre-diabetes, or in animals with type 2 or type 1 diabetes mellitus or pre-diabetes.
